AzTrials
AzTrials

Geographic Atrophy Secondary to Age-related Macular DegenerationPhase 3GALENCT04770545

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD

A Phase 3 study testing PEGCETACOPLAN (APL-2) in people with Geographic Atrophy Secondary to Age-related Macular Degeneration, run by Apellis Pharmaceuticals, Inc. at 175 sites in 15 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who participated in Study APL2-103 (NCT03777332) or completed the treatment at Month 24 of… Read more about this study

Who is it for?
Ages 60 years and older
What is being tested?
PEGCETACOPLAN (APL-2)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
792 participants
Where
175 sitesin 15 countries
Study dates
4 Mar 2021to 5 Sep 2025
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 60 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Participants are eligible to be included in the study only if all of the following criteria apply:
  • Ocular-specific inclusion criteria apply to the study eye only.
  • Subjects must have participated in APL2-103 (NCT03777332) or completed the treatment at Month 24 of either APL2-303 (Derby, NCT03525613) or APL2-304 (Oaks, NCT03525600).
  • For subjects who participated in either the 303 or 304 studies, the condition listed below must also be met for participating in this study.
  • Subjects who did not fully stop study drug treatment, but missed the visit at Month 24, can also participate in the study. However, to participate, subjects must be seen within 60 days from the last day of the period allowed for the 24 months visit in the previous study.
  • The eyes of subjects must have transparency to permit visualization of parts inside the eye such as the retina and subjects must be able to look steadily at a provided target allowing the doctor to get good quality pictures from the eye.
Show all 11Show fewer
  • Female subjects must be:
  • Women that cannot have children, or
  • Women who can have children must have a negative result of a blood pregnancy test on the first day of the study visit and agree to use ways to avoid pregnancy during the study and 90 days after the last dose of the study medication.
  • Males with female partners who can get pregnant must also agree to use ways to avoid pregnancy and agree not to donate sperm while in the study or until 90 days after administering the last dose of the study medication.
  • Agree to participate in the study by signing the consent document providing information about the study; and take part in all tests and assessments as required.

Who cannot join

  • Subjects cannot take part in the study if the eye that will be treated during the study currently meets any of the following conditions:
  • Participants in APL2 303/304 studies who fully stopped study drug treatment before the visit in month 24 but remain in the study to observe the study medication's safety. Those subjects who temporarily paused study drug treatment are still eligible to participate.
  • If, according to your doctor you currently have any disease affecting your eyes that could interfere with your vision, including diseases that affect your retina or macula (the center of the back of your eyes). And, if according to your doctor, the disease in your eyes is benign and does not interfere with the study (e.g. diseases that affects the periphery of the retina), you are also eligible to take part in the study.
  • If, according to your doctor you currently have any inflammation/infection in or around your eyes that could prohibit you from receiving an injection inside your eyes.
  • If, according to your doctor, any current disease that could directly interfere in your participation in the study or that could make it difficult for you to come to the scheduled visits during the next three years over the next 36 months.
  • If you have known allergies to fluorescein sodium, a solution that is injected into your body for eye testing; or to pegcetacoplan (the study drug) or any inactive substances in pegcetacoplan solution.
  • If you currently are pregnant, breastfeed or have a positive pregnancy test.

Trial locations and contacts

175 sites in 15 countries.

175 sites in 15 countries

United States99 sites
  • Vision Research Center Eye Associates of NM

    Albuquerque, New Mexico, 87109

  • Michigan Medicine Kellogg Eye Center

    Ann Arbor, Michigan, 48105

  • Western Carolina Retinal Associates

    Asheville, North Carolina, 28803

  • Southeast Retina Center, PC

    Augusta, Georgia, 30909

  • Retina Research Center PLLC

    Austin, Texas, 78750

  • California Retina Consultants

    Bakersfield, California, 93309

  • The Retina Care Center

    Baltimore, Maryland, 21209

  • Elman Retina Group

    Baltimore, Maryland, 21236

  • Brown Retina Institute

    Bellaire, Texas, 77401

  • Vitreoretinal Associates of Washington

    Bellevue, Washington, 98004

  • Mid Atlantic Retina

    Bethlehem, Pennsylvania, 18107

  • Retina Center of NJ, LLC

    Bloomfield, New Jersey, 07003

  • Gailey Eye Clinic Retina Center

    Bloomington, Illinois, 61704

  • Ophthalmic Consultants of Boston

    Boston, Massachusetts, 02114

  • Tufts Medical Center

    Boston, Massachusetts, 02116

  • Florida Eye Microsurgical Institute, Inc.

    Boynton Beach, Florida, 33426

  • Retinal Diagnostic Center

    Campbell, California, 95508

  • Charlotte Eye Ear Nose and Throat Associates, PS

    Charlotte, North Carolina, 28210

  • University of Virginia

    Charlottesville, Virginia, 22903

  • The Retina Group of Washington

    Chevy Chase, Maryland, 20815

  • Northwestern Feinberg School of Medicine

    Chicago, Illinois, 60611

  • Rush University Medical Center

    Chicago, Illinois, 60612

  • Blue Ocean Clinical Research

    Clearwater, Florida, 33761

  • Retina Associates of Cleveland, Inc.

    Cleveland, Ohio, 44122

  • Retina Associates of Cleveland

    Cleveland, Ohio, 44130

  • Cleveland Clinic Cole Eye Institute

    Cleveland, Ohio, 44195

  • The Ohio State University

    Columbus, Ohio, 43212

  • Texas Retina Associates

    Dallas, Texas, 75231

  • Danbury Eye Physicians & Surgeons, PC

    Danbury, Connecticut, 06810

  • Southwest Retina Research Center, LLC

    Durango, Colorado, 81301

  • Duke University, Duke Eye Center

    Durham, North Carolina, 27710

  • Retina Vitreous Center, PLLC

    Edmond, Oklahoma, 73013

  • The Retina Partners

    Encino, California, 91436

  • Oregon Retina LLP

    Eugene, Oregon, 97405

  • The Retina Group of Washington

    Fairfax, Virginia, 22031

  • Emerson Clinical Research Institute

    Falls Church, Virginia, 22046

  • Pinnacle Research Institute

    Fort Lauderdale, Florida, 33309

  • Retina Health Center

    Fort Myers, Florida, 33907

  • National Ophthalmic Research Institute

    Fort Myers, Florida, 33912

  • Retina Consultants of Orange County

    Fullerton, California, 92835

  • Charles Retina Institute

    Germantown, Tennessee, 38138

  • Associated Retinal Consultants, PC

    Grand Rapids, Michigan, 49546

  • Long Island Vitreoretinal Consultants

    Great Neck, New York, 11021

  • Cumberland Valley Retina Center

    Hagerstown, Maryland, 21740

  • Mid Atlantic Retina Specialist

    Hagerstown, Maryland, 21740

  • Graystone Eye

    Hickory, North Carolina, 28602

  • Houston Eye Associates

    Houston, Texas, 77025

  • Retina Consultants of Houston, PA

    Houston, Texas, 77030

  • Atlantis Eyecare

    Huntington Beach, California, 92647

  • Midwest Eye Institute

    Indianapolis, Indiana, 46290

  • Jacobs Retina Center, UCSD

    La Jolla, California, 92093

  • Retina and Vitreous Associates of Kentucky, PSC dba Retina Associates of Kentucky

    Lexington, Kentucky, 40509

  • Doheny Eye Center UCLA

    Los Angeles, California, 90033

  • Retina Health Center

    Madison, Wisconsin, 53705

  • Retina-Vitreous Associates Medical Group

    Madison, Wisconsin, 53705

  • Georgia Retina, PC

    Marietta, Georgia, 30060

  • Valley Retina Institute

    McAllen, Texas, 78503

  • Bascom Palmer Eye Institute

    Miami, Florida, 33136

  • Vitreoretinal Surgery

    Minneapolis, Minnesota, 55435

  • Retina Vitreous Consultants

    Monroeville, Pennsylvania, 15146

  • Northern California Retina Vitreous Associates

    Mountain View, California, 94040

  • Retina Associates of Utah, PC

    Murray, Utah, 84107

  • Bascom Palmer Eye Institute at Naples

    Naples, Florida, 34103

  • Tennessee Retina, PC

    Nashville, Tennessee, 78503

  • Vitreous Retina Macula Consultants of New York

    New York, New York, 10022

  • Ophthalmic Consultants of Long Island

    Oceanside, New York, 11572

  • Palm Beach Gardens

    Palm Beach Gardens, Florida, 33418

  • Retina Institute of California Medical Group

    Palm Desert, California, 92260

  • Byers Eye Institute, Stanford University

    Palo Alto, California, 94303

  • Retina Specialty Institute

    Pensacola, Florida, 32503

  • Mid Atlantic Retina

    Philadelphia, Pennsylvania, 19006

  • Mid Atlantic Retina

    Philadelphia, Pennsylvania, 19107

  • Retinal Research Institute, LLC

    Phoenix, Arizona, 85014

  • Associated Retina Consultants, Ltd.

    Phoenix, Arizona, 85020

  • Eye Associates of Pinellas

    Pinellas Park, Florida, 33782

  • Retina Northwest, PC

    Portland, Oregon, 97221

  • Eye Health Northwest

    Portland, Oregon, 97225

  • Retina Consultants San Diego

    Poway, California, 92064

  • Black Hills Regional Eye Institute

    Rapid City, South Dakota, 57701

  • Sierra Eye Associates

    Reno, Nevada, 89503

  • University of Utah - John A. Moran Center

    Salt Lake City, Utah, 84312

  • Medical Center Ophthalmology Associates

    San Antonio, Texas, 78240

  • Retina Associates of South Texas

    San Antonio, Texas, 78240

  • Orange County Retina Medical Group

    Santa Ana, California, 92705

  • California Retina Consultants

    Santa Barbara, California, 93103

  • Spokane Eye Clinical Research

    Spokane, Washington, 99204

  • New England Retina Consultants, PC

    Springfield, Massachusetts, 01107

  • East Florida Eye Institute

    Stuart, Florida, 34994

  • Retina Associates of Florida

    Tampa, Florida, 33609

  • University of South Florida

    Tampa, Florida, 33612

  • NJ Retina

    Teaneck, New Jersey, 07666

  • Retina Consultants of Houston

    The Woodlands, Texas, 77384

  • NJ Retina

    Toms River, New Jersey, 08755

  • Associated Retinal Consultants, PC

    Traverse City, Michigan, 49686

  • Bay Area Retina Associates

    Walnut Creek, California, 94598

  • Retina Group of New England - New London

    Waterford, Connecticut, 06835

  • AIO Visionary Eye Care

    West Mifflin, Pennsylvania, 15122

  • Center for Retina and Macular Disease

    Winter Haven, Florida, 33880

  • Retina Associates of Cleveland, Inc.

    Youngstown, Ohio, 44505

Other trials in United States

France14 sites
  • CHU de Bordeaux

    Bordeaux, 33076

  • Centre Hospitalier Intercommunal de Creteil

    Créteil, 94010

  • CHU Dijon

    Dijon, 21 079

  • Clinique du Val d'Ouest

    Écully, 69130

  • Hopital de la Croix-Rousse

    Lyon, 69004

  • Centre monticelli Paradis

    Marseille, 13008

  • CHU de Nantes - Hotel Dieu

    Nantes, 44093

  • Centre Ophtalmol de l Odeon

    Paris, 75006

  • Hopital Lariboisiere

    Paris, 75010

  • CHNO des Quinze-Vingts

    Paris, 75012

  • Centre Ophtalmo. Image/Laser

    Paris, 75015

  • Centre ophtalmologique Saint-Exupery

    Saint-Cyr-sur-Loire, Lyon, 37540

  • Maison Rouge Ophthalmologic Center

    Strasbourg, 67000

  • CHU de Strasbourg Hopital Civil

    Strasbourg, 67091

Other trials in France

Germany12 sites
  • Universitats-Augenklinik Bonn

    Bonn, 53127

  • Uniklinik Koln

    Cologne, 50937

  • University Opthalmology Clinic

    Freiburg im Breisgau, 79106

  • Uni-medizin Gottingen Augenklinik 3.B1.261

    Göttingen, 37075

  • Universitatsklinikum Schleswig-Holstein

    Lübeck, 23538

  • Klinikum der Stadt Ludwigshafen gGmbH

    Ludwigshafen, 67063

  • Augenklinik der LMU Munchen

    München, 80336

  • Klinikum rechts der Isar

    München, 81675

  • Augenzentrum am St. Franziskus-Hospital

    Münster, 48145

  • Universitatsklinikum Regensburg

    Münster, 48145

  • Universitatsklinikum Munster

    Münster, 48149

  • STZ Eyetrial

    Tübingen, 72076

Other trials in Germany

Argentina8 sites
  • Diagnostico Ocular

    Buenos Aires, 1425

  • Organizacion Medica de Investigacion (OMI)

    Buenos Aires, C1015 ABO

  • Fundacion Zambrano

    Buenos Aires, C1023 AAQ

  • Centro Oftalmologico Dr. Charles S.A.

    Buenos Aires, C1116ABA

  • Instituto Oftalmologico de Cordoba

    Córdoba, 5000

  • OFTAR

    Mendoza, 5500

  • Microcirujia Ocular Rosario

    Rosario, 2000

  • Oftalmologos Especialistas

    Santa Fe, S2000

Other trials in Argentina

Australia8 sites
  • Centre for Eye Research Australia

    East Melbourne, Victoria, 3002

  • Retina and Eye Consultantss

    Hurstville, 2220

  • Lions Eye Institute

    Nedlands, 6009

  • Marsden Eye Specialist

    Parramatta, New South Wales, 2150

  • Strathfield Retina Clinic

    Strathfield, New South Wales, 2135

  • Sydney Retina

    Sydney, New South Wales, 2000

  • The Ashley Centre

    Westmead, New South Wales, 2145

  • Save Sight Institute

    Westmead, 2145

Other trials in Australia

United Kingdom8 sites
  • Bristol Eye Hospital

    Bristol, BS1 2LX

  • Huddersfield Royal Infirmary

    Huddersfield, West Yorkshire, HD3 3EA

  • St James's University Hospital

    Leeds, West Yorkshire, LS9 7TF

  • Royal Liverpool University Hospital

    Liverpool, L7 8XP

  • Kings College Hospital NHS Trust

    London, SE5 9RS

  • London Vision Clinic

    London, W1G 7LA

  • Oxford Eye Hospital

    Oxford, OX3 9DU

  • Sunderland Eye Infirmary

    Sunderland, SR2 9HP

Other trials in United Kingdom

Czechia5 sites
  • Fakultni Nemocnice Ostrava

    Ostrava-Poruba, 708 52

  • University hospital Kralovske Vinohrady

    Prague, 10034

  • AXON Clinical, s.r.o.

    Prague, 150 00

  • Vseobecna fakultni nemocnice v Praze

    Prague, 2128 08

  • Gemini Eye Clinic

    Zlín, 760 01

Other trials in Czechia

Poland5 sites
  • Eye Surgery Center Professor Zagorski

    Bydgoszcz, 85-316

  • Oftalmika Eye Hospital

    Bydgoszcz, 85-631

  • Grupo Laser Vision

    Rzeszów, 35-017

  • Oculomedica Eye Centre

    Tarnów, 33-100

  • UNO-MED Centrum Medyne

    Tarnów, 33-100

Other trials in Poland

Israel4 sites
  • Assaf ha Rofeh MC

    Be’er Ya‘aqov, 7030000

  • Rambam Health Care Campus

    Haifa, 3109601

  • Hadassah Medical Center

    Jerusalem, 91120

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, 64239

Other trials in Israel

Canada3 sites
  • Ivey Eye Institute

    London, Ontario, N6A 4V2

  • University of Ottawa Eye Institute

    Ottawa, Ontario, K1H 8L6

  • Retina Centre of Ottawa

    Ottawa, Ontario, K2B 7E9

Other trials in Canada

Italy2 sites
  • IRCCS San Raffaele

    Milan, 20132

  • ASST Fatebenefratelli-Sacco Ospedale Luigi Sacco

    Milan, 20157

Other trials in Italy

Netherlands2 sites
  • Academisch Medisch Centrum

    Amsterdam, 1105 AZ

  • Radboud university medical center Oogheelkunde

    Nijmegen, 6525 EX

Other trials in Netherlands

New Zealand2 sites
  • Southern Eye Specialists

    Christchurch, 8013

  • Hamilton Eye Clinic

    Hamilton, 3204

Other trials in New Zealand

Spain2 sites
  • Hospital Universitario Puerta de Hierro

    Madrid, 28222

  • Instituto Oftalmologico Gomez-Ulla

    Santiago de Compostela, 15706

Other trials in Spain

Brazil1 site
  • IPEPO Instituto Da Visao

    São Paulo, 04038-032

Other trials in Brazil

About this study

Official title: A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who participated in Study APL2-103 (NCT03777332) or completed the treatment at Month 24 of either Study APL2-303 (Derby, NCT03525613) or Study APL2-304 (Oaks, NCT03525600).

Being tested
PEGCETACOPLAN (APL-2)

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PEGCETACOPLAN (APL-2)Drug

    Complement (C3) Inhibitor

Study groups in NCT04770545
Study groupRoleWhat they receive
Monthly: Pegcetacoplan/ PegcetacoplanExperimentalParticipants who received monthly intravitreal (IVT) pegcetacoplan (15 milligrams [mg]/100 microlitres [μL]) in the antecedent studies (APL2-103 [NCT03777332], APL2-303 [NCT03525600], and APL2-304 [NCT03525613]) continued to receive monthly IVT pegcetacoplan (15 mg/100 μL) for up to 36 months.
Receives: Drug: PEGCETACOPLAN (APL-2)
EOM: Pegcetacoplan/PegcetacoplanExperimentalParticipants who received IVT pegcetacoplan (15 mg/100 μL) every other month (EOM) in the antecedent studies (APL2-103 [NCT03777332], APL2-303 [NCT03525600], and APL2-304 [NCT03525613]) continued to receive IVT pegcetacoplan (15 mg/100 μL) EOM for up to 36 months.
Receives: Drug: PEGCETACOPLAN (APL-2)
Monthly: Sham/PegcetacoplanExperimentalParticipants who received sham monthly in the antecedent studies (APL2-103 [NCT03777332], APL2-303 [NCT03525600], and APL2-304 [NCT03525613]) received monthly IVT pegcetacoplan (15 mg/100 μL) for up to 36 months.
Receives: Drug: PEGCETACOPLAN (APL-2)
EOM: Sham/PegcetacoplanExperimentalParticipants who received sham EOM in the antecedent studies (APL2-103 [NCT03777332], APL2-303 [NCT03525600], and APL2-304 [NCT03525613]) received IVT pegcetacoplan (15 mg/100 μL) EOM for up to 36 months.
Receives: Drug: PEGCETACOPLAN (APL-2)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants Who Experienced at Least One Ocular and Systemic Adverse Events (AEs)

    An AE is any untoward medical occurrence associated with use of a drug in humans, whether or not it is considered study drug-related. An AE can, therefore, be any unfavorable and unintended sign, including a clinically significant abnormal laboratory finding, symptom, or disease temporally associated with the use of an investigational product, whether considered related to the investigational product.

    Measured: From Day 1 up to Month 36

Secondary outcomes (17)
  1. Change From Baseline in Total Area of Geographic Atrophy (GA) Lesion(s) in the Study Eye

    The change in GA lesion area was measured by a qualified central reading center based on fundus autofluorescence (FAF) images.

    Measured: Baseline, Months 12, 24 and 36

  2. Change From Baseline in the Rate of GA Lesion Growth in the Study Eye

    The mean rate of change in GA area was analyzed by use of a piecewise linear mixed effect model assuming time as continuous and piecewise linear in FAS based on FAF images.

    Measured: Baseline, Months 12, 24 and 36

  3. Change From Baseline in Normal-Luminance Best-Corrected Visual Acuity (NL-BCVA) Score of the Study Eye

    The NL-BCVA was assessed by early treatment diabetic retinopathy study (ETDRS) chart prior to dilating the eyes at a starting distance of 4 meters and ranged from 0 (least score) to 100 (best score). If the 4-meter score was >19 letters read correctly, the visual acuity score was the sum of total letters correctly read at 4 meters plus the addition of 30. If the 4-meter score was ≤19 letters read correctly, the visual acuity score was the sum of total letters read correctly at 4 meters and total letters read correctly at the 1-meter distance. If no letters were read correctly at either the 4-meter distance or the 1-meter distance, the visual acuity score was 0. A negative change from baseline indicates loss in visual acuity.

    Measured: Baseline, Months 12, 24 and 36

  4. Change From Baseline in Low-Luminance Best-Corrected Visual Acuity (LL-BCVA) Score of the Study Eye

    The LL-BCVA was assessed by early treatment diabetic retinopathy study (ETDRS) chart prior to dilating the eyes at a starting distance of 4 meters and ranged from 0 (least score) to 100 (best score). It was measured by placing a neutral density trial lens causing a reduction of 2.0 log units in luminance. If the 4-meter score was >19 letters read correctly, the visual acuity score was the sum of total letters correctly read at 4 meters plus the addition of 30. If the 4-meter score was ≤19 letters read correctly, the visual acuity score was the sum of total letters read correctly at 4 meters and total letters read correctly at the 1-meter distance. If no letters were read correctly at either the 4-meter distance or the 1-meter distance, the visual acuity score was 0. A negative change from baseline indicates loss in visual acuity.

    Measured: Baseline, Months 12, 24 and 36

  5. Change From Baseline in Monocular Maximum Corrected Reading Speed of the Study Eye

    The maximum reading speed of the study eye was calculated per Minnesota Low-Vision Reading Test (MNRead) or Radner user manuals, with adjustment for reading inaccuracy. An additional step to cap resulting reading speed values at a maximum of 300 words per minute was implemented. Maximum reading speed was calculated as the mean of the three highest nonzero reading speeds (or two, or one value, as available), except when all words per minute were calculated as 0: then the maximum reading speed was calculated as 0. A negative change from baseline indicated a decrease in the monocular reading speed; disease worsening.

    Measured: Baseline, Months 12, 24 and 36

  6. Change From Baseline in Binocular Maximum Corrected Reading Speed

    The maximum reading speed was calculated per MNRead or Radner user manuals, with adjustment for reading inaccuracy. An additional step to cap resulting reading speed values at a maximum of 300 words per minute was implemented. Maximum reading speed was calculated as the mean of the three highest nonzero reading speeds (or two, or one value, as available), except when all words per minute were calculated as 0: then the maximum reading speed was calculated as 0. A negative change from baseline indicated a decrease in the binocular reading speed; disease worsening.

    Measured: Baseline, Months 12, 24 and 36

  7. Change From Baseline in Number of Scotomatous Points of the Study Eye

    The number of absolute scotomatous points was determined from mesopic microperimetry as an assessment of the macular functional response.

    Measured: Baseline, Months 12, 24 and 36

  8. Change From Baseline in Macular Sensitivity of the Study Eye

    Macular sensitivity was assessed by mesopic microperimetry. A negative change from baseline indicates a decrease in the macular sensitivity.

    Measured: Baseline, Months 12, 24 and 36

  9. Change From Baseline in 95% Bivariate Contour Ellipse Area (BCEA) Degrees Squared (Deg²) of the Study Eye

    Microperimetry was conducted to assess the bivariate contour ellipse area 95%.

    Measured: Baseline, Months 12, 24 and 36

  10. Mean Change From Baseline in Functional Reading Independence (FRI) Index Score

    The FRI index is an individualized assessment of functional reading independence. The questionnaire has 7 items with one total index score. Scores derived from the index range from 1 (unable to do independently) to 4 (total independence) with higher scores indicating higher functional reading independence. A negative change from baseline indicated a decrease in the FRI; disease worsening. Least squares mean was calculated using a mixed effect model for repeated measure (MMRM) model.

    Measured: Baseline, Months 12, 24 and 36

  11. Change From Baseline in National Eye Institute Visual Functioning Questionnaire 25-Item Version (NEI VFQ-25) Composite Score

    The NEI-VFQ-25 is an interviewer-administered questionnaire designed to assess participant-reported visual function. It is a 25-item questionnaire with a composite score and covers 12 domains of functional health status and well-being (general health, general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, and peripheral vision). Scoring yields 12 subscales based on the 12 domains covered in the questionnaire. These scales are scored from 0 to 100 with higher scores indicating better visual function. A composite score is the average of the vision-targeted sub-scale scores, excluding the general health rating question. A negative change from baseline indicated a decrease in visual functioning; disease worsening.

    Measured: Baseline, Months 12, 24 and 36

  12. Change From Baseline in NEI VFQ-25 Near Activity Subscale Score

    The NEI-VFQ-25 is an interviewer-administered questionnaire designed to assess participant-reported visual function. It is a 25-item questionnaire with a composite score and covers 12 domains of functional health status and well-being (general health, general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, and peripheral vision). Scoring yields 12 subscales based on the 12 domains covered in the questionnaire. The possible score range is 0 to 100 with higher scores indicating better visual function. A negative change from baseline indicated a decrease in visual functioning; disease worsening. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf.

    Measured: Baseline, Months 12, 24 and 36

  13. Change From APL2-GA-305 Baseline in NEI VFQ-25 Distance Activity Subscale Score

    The NEI-VFQ-25 is a 25-item questionnaire with a composite score and covers 12 domains of functional health status and well-being. A distance activity subscale score one of the domains is the average of 3 items: 8 (How much difficulty do you have reading street signs or the names of stores?), 9 (Because of your eyesight, how much difficulty do you have going down steps, stairs, or curbs in dim light or at night?) and 14 (Because of your eyesight, how much difficulty do you have going out to see movies, plays, or sports events?). The possible score range is 0 to 100, with higher scores indicating better visual function. A negative change from baseline indicated a decrease in visual functioning; disease worsening.

    Measured: Baseline, Months 12, 24 and 36

  14. Change From Baseline in NEI VFQ-25 Driving Subscale Score

    The NEI-VFQ-25 is a 25-item questionnaire with a composite score and covers 12 domains of functional health status and well-being. A driving subscale score one of the domains is the average of 3 items: 15c (If currently driving: How much difficulty do you have driving during the day time in familiar places?), 16 (How much difficulty do you have driving at night), and 16a (How much difficulty do you have driving in difficult conditions, such as in bad weather, during rush hour, on the freeway, or in city traffic?). The possible score range is 0 to 100, with higher scores indicating better visual function. A negative change from baseline indicated a decrease in visual functioning; disease worsening.

    Measured: Baseline, Months 12, 24 and 36

  15. Change From Baseline in National Eye Institute Visual Functioning Questionnaire 39-Item Version (NEI VFQ-39) Composite Score

    NEI-VFQ-25 includes 13 additional items under 7 subscales related to general health, general vision, near vision, distance vision, social function, driving, role limitations, well-being or distress and dependency that allow for the calculation of NEI-VFQ-39 scores. The NEI-VFQ composite score is obtained by averaging the vision-related subscales, excluding the general health rating question. The possible score range is 0 to 100, with higher scores indicating better visual function. A negative change from baseline indicated a decrease in visual functioning; disease worsening.

    Measured: Baseline, Months 12, 24 and 36

  16. Change From Baseline in NEI VFQ-39 Near Activity Subscale Score

    NEI-VFQ-25 includes 13 additional items under 7 subscales, enabling calculation of NEI-VFQ-39 scores. NEI-VFQ near activity subscale score is obtained by averaging 6 items: 5 (How much difficulty do you have reading ordinary print in newspapers), 6 (How much difficulty do you have doing work/hobbies that require you to see up close?), 7 (Because of your eyesight, how much difficulty do you have finding something on a crowded shelf?), A3 (Wearing glasses, how much difficulty do you have reading the small print in a telephone book, on medicine bottle, or on legal forms?), A4 (Because of your eyesight, how much difficulty do you have figuring out bills you receive are accurate?) \& A5 (Because of your eyesight, how much difficulty do you have doing things like shaving, styling your hair or putting on makeup). The possible score range is 0 to 100, with higher scores indicating better visual function. A negative change from baseline indicated reduced visual functioning; disease worsening.

    Measured: Baseline, Months 12, 24 and 36

  17. Change From Baseline in NEI VFQ-39 Distance Activity Subscale Score

    NEI-VFQ-25 includes 13 additional items under 7 subscales, enabling calculation of NEI-VFQ-39 scores. NEI-VFQ near activity subscale score is obtained by averaging 6 items: 8 (How much difficulty do you have reading street signs/names of stores?), 9 (Because of your eyesight, how much difficulty do you have going down steps, stairs/ curbs in dim light/ at night?) and 14 (Because of your eyesight, how much difficulty do you have going out to see movies, plays/sports events?), A6 (Because of your eyesight, how much difficulty do you have recognizing people you know from across a room?), A7 (Because of your eyesight, how much difficulty do you have taking part in active sports/other outdoor activities?) \& A8 (Because of your eyesight, how much difficulty do you have seeing \& enjoying programs on TV?). The possible score range is 0 to 100, with higher scores indicating better visual function. A negative change from baseline indicated reduced visual functioning; disease worsening.

    Measured: Baseline, Months 12, 24 and 36

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Feb 2021
  2. Study start4 Mar 2021
  3. Primary completion5 Sep 2025
  4. Study completion5 Sep 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
792 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04770545
Sponsor's protocol ID
APL2-GA-305
Acronym
GALE
Status last verified
Oct 2026
First submitted
23 Feb 2021
Last updated
28 Oct 2026
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing PEGCETACOPLAN (APL-2) in people with Geographic Atrophy Secondary to Age-related Macular Degeneration, run by Apellis Pharmaceuticals, Inc. at 175 sites in 15 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 175 sites in United States, France, Germany, Argentina, Australia and 10 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 28 Oct 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants Who Experienced at Least One Ocular and Systemic Adverse Events (AEs) (time frame: From Day 1 up to Month 36). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in